摘要
目的:观察来氟米特联合泼尼松治疗狼疮肾炎患者的效果。方法:选取2021年6月至2023年2月该院收治的90例狼疮肾炎患者进行前瞻性研究,按照随机数字表法将其分为观察组和对照组各45例。对照组予以泼尼松治疗,观察组在对照组基础上联合来氟米特治疗,两组均连续治疗6个月。比较两组临床疗效,治疗前后肾功能指标[24 h尿蛋白定量、血肌酐(Scr)、血尿素氮(BUN)]水平、炎性指标[C反应蛋白(CRP)、白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)]水平、系统性红斑狼疮疾病活动度(SLEDAI)评分,以及不良反应发生率。结果:观察组治疗总有效率为93.33%(42/45),高于对照组的77.78%(35/45),差异有统计学意义(P<0.05);治疗后,观察组24 h尿蛋白定量、Scr、BUN水平均低于对照组,差异有统计学意义(P<0.05);治疗后,观察组CRP、IL-6、TNF-α水平均低于对照组,差异有统计学意义(P<0.05);治疗后,观察组SLEDAI评分低于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:来氟米特联合泼尼松治疗狼疮肾炎患者可提高治疗总有效率,降低肾功能指标水平、炎性指标水平和SLEDAI评分,效果优于单纯泼尼松治疗。
Objective:To observe effects of Leflunomide combined with Prednisone in treatment of patients with lupus nephritis.Methods:A prospective study was conducted on 90 patients with lupus nephritis admitted to the hospital from June 2021 to February 2023.According to the random number table method,they were divided into observation group and control group,45 cases in each group.The control group was treated with Prednisone,while the observation group was treated with Leflunomide on the basis of that of the control group.Both groups were treated continuously for 6 months.The clinical efficacy,the renal function indexes[24 h urine protein quantification,serum creatinine(Scr),blood urea nitrogen(BUN)]levels,the inflammatory indexes[C-reactive protein(CRP),interleukin-6(IL-6),tumor necrosis factor-α(TNF-α)]levels,the systemic lupus erythematosus disease activity(SLEDAI)score,and the incidence of adverse reactions were compared between the two groups before and after the treatment.Results:The total effective rate of the observation group was 93.33%(42/45),which was higher than 77.78%(35/45)of the control group,and the difference was statistically significant(P<0.05).After the treatment,the levels of 24 h urinary protein,Scr and BUN in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the levels of CRP,IL-6 and TNF-αin the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the SLEDAI score of the observation group was lower than that of the control group,and the difference was statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Leflunomide combined with Prednisone in the treatment of the patients with lupus nephritis can improve the total effective rate of treatment and reduce the levels of renal function indexes and inflammatory indexes and the SLEDAI scores.Moreover,it is superior to single Prednisone treatment.
作者
李金
LI Jin(Department of Nephrology and Rheumatology of Xihua County People’s Hospital,Zhoukou 466600 Henan,China)
出处
《中国民康医学》
2024年第7期59-61,共3页
Medical Journal of Chinese People’s Health
关键词
狼疮性肾炎
泼尼松
来氟米特
肾功能
疾病活动度
不良反应
Lupus nephritis
Prednisone
Leflunomide
Renal function
Disease activity
Adverse reaction
